Our products

CNX Therapeutics commercialises the speciality brand CNS drug Latuda in the UK and direct markets across Europe. In addition, we manage a portfolio of niche hospital products for a range of therapy areas including oncology, anti-infectives and endocrinology.

We are seeking to expand our product portfolio and are open to in-licensing, co-promotion, revenue-sharing, and other partnering opportunities.

Please also reach out to us to discuss out-licensing opportunities available for global commercialisation.

Speciality Brands

Please click on the product for more information.

LATUDA® (lurasidone)

Adverse reactions must be reported

Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Speciality Brands Adverse Reactions:
+44 (0) 20 7821 2899

Hospital Products

Please click on each product for more information.

Chlorphenamine
10mg/ml in 1ml
Cyclizine
50mg/ml in 1ml amps
Dexamethasone
10mg/5ml oral solution
Dexamethasone
20mg/5ml oral solution
Doxapram
20mg/ml in 1ml amps
Gemcitabine
200mg vial
Gemcitabine
1000mg vial

Labetalol
5mg in 10ml amps
Magnesium Sulfate
10% amps 10ml
Magnesium Sulfate
20% amps 10ml
Magnesium Sulfate
20% amps 20ml
Meropenem
500mg vial
Meropenem
1g vial

Adverse reactions must be reported

Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Hospital Products Adverse Reactions:
+44 (0) 14 3879 1091

Business Development

Dossiers Available

Bortezomib
3.5mg vial
Chlorphenamine
10mg/ml in 1ml
Cyclizine
50mg/ml in 1ml amps
Doxapram
20mg/ml in 1ml amps

Magnesium Sulfate
20% amps 10ml
Pemetrexed
500mg vial
Zoledronic Acid
4mg vial
Zoledronic Acid
5mg vial

In-Licensing

CNX Therapeutics is seeking to expand its product portfolio in Europe and selected global markets.

Our business development activities are focused on approved prescription branded and generic products.

We are open to in-licensing, co-promotion, revenue-sharing, and other partnering opportunities.

We are primarily interested in pharmaceutical products for diseases of the central nervous system, but will consider broader therapy areas if we are able to add value when commercialising.

If you’d like to contact us, please use the form on our Contact page.